Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report)‘s stock had its “market perform” rating reiterated by Leerink Partners in a note issued to investors on Monday,Benzinga reports. They currently have a $641.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $792.00. Leerink Partners’ price objective indicates a potential downside of 8.20% from the company’s previous close.
Several other research analysts have also commented on REGN. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating on the stock in a report on Thursday, April 30th. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Finally, Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $818.52.
Read Our Latest Stock Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Price Performance
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $8.22 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals will post 37.1 earnings per share for the current year.
Insider Activity
In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 6.97% of the company’s stock.
Institutional Trading of Regeneron Pharmaceuticals
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after buying an additional 26,884 shares during the last quarter. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after buying an additional 45,513 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after buying an additional 106,861 shares during the last quarter. Nuveen LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares during the last quarter. Finally, Capital World Investors increased its holdings in shares of Regeneron Pharmaceuticals by 1.6% during the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock valued at $1,123,609,000 after acquiring an additional 32,348 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals News Roundup
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Regeneron announced a new collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates, potentially expanding its pipeline into hard-to-drug targets and creating long-term upside. Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
- Neutral Sentiment: The Parabilis agreement includes a $50 million upfront payment, a $75 million equity commitment, and future milestones/royalties, which is meaningful but still dependent on early-stage scientific success. Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
- Negative Sentiment: Regeneron’s phase 3 melanoma study of fianlimab failed to meet its main goal, a setback that weakens confidence in the company’s near-term oncology growth story. Regeneron drops after skin cancer treatment misses late-stage trial goal
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- 3 Infrastructure Stocks Fueling the Data Center Building Boom
- Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks
- As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
